All statements are my own opinion - if your looking for investment advice, go ask someone else - I’m not qualified to help you, so don’t ask.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT - Somewhere around October 11, 2012, Shutterstock started trading.
...just thought that this may be a preferred time of the year to make an announcement.
The company priced its IPO at $17 a share and saw the stock rise more than 30% in trading before closing the day at $21.66, a gain of 27.4%. Shutterstock was expected to IPO for $13-$15 a share.
Q&A With Jon Oringer, Founder And CEO, Shutterstock
http://mashable.com/2012/10/11/shutterstock-ipo-closes-up/#NYsl01naMGqw
I'm still not convinced, but I took an initial position this morning @ 15.
If it goes great, if not, I should have known better.
I think I'll go have more coffee.
Limitless609
Why has the volume been low?
Look at the last month of trading. The first 2 weeks had great volume.
The last 2 weeks has had minimal volume.
I don't know if there will be a dip in share price this week, but it would
not surprise me.
Low volume linked to a share-price increase is a negative sign.
Any lasting upward price movement should be confirmed with increasing volume.
others on the board are saying it;s life changing.
I'm not sure - I'm still on the fence.
I find it hard to believe that only a few people are "in-the-know"
I've been watching this for weeks; I have a difficult time believing that this is kept so quiet as to be a life-changing experience for all of those "in-the-know".
I don't think we are going to hear anything until after October 15th based on:
The Option and Separation Agreement .
Pursuant to an option and separation agreement, dated as of May 16, 2016 (the “Separation Agreement”) between the Company and Leonard Caprino, the President of Solaris, Mr. Caprino agreed as of May 31, 2016 (the “Termination Date”) to voluntarily resign as an executive officer and member of the board of directors of the Company. Under the Separation Agreement, the Company agreed to pay accrued and unpaid compensation and other obligations to Mr. Caprino valued at $150,000 by the issuance to Mr. Caprino of (a) 1,000,000 shares of the Company’s Series A Preferred Stock, and (b) a convertible $100,000 Company note due on October 15, 2016 (the “Severance Note’), the payment of which is to be secured by a lien on the Company’s existing assets, consisting of existing assets, consisting of the Solaris Sun Car Golf Carts, Solaris Sun Car EZ Go Model, Solaris F2 Vapor Mod and associated PESA Electronics, associated PESA Cell storage arrays, and related technology, as well as domain names relating to such assets. The Severance Note is convertible into Company Common Stock at a conversion price equal to the volume weighted average price of Company Common Stock as of the date notice of conversion is given by the holder of the Severance Note. In addition, the agreement with Mr. Caprino grants him an option, exercisable at any time commencing July 15, 2016 and ending December 31, 2016 (the “Option Period”) to purchase the Existing Solaris Assets for the sum of $60,000; which amount is payable by Mr. Caprino either in cash or by reducing a like amount of the Severance Note.
- I'm still on the fence....
Are you saying the DCAC is the most shorted stock in the OTC? Or, are you just providing short data?
I think there is more to this relationship DCAC has with CWTC. Looks like CWTC is up for a symbol change; a move off the pinks?
I thought for sure we would have a press release by this week. It seems overdue. Best Wishes to all!
I think we will have a multiple press releases this month. GLTA!
I hope you get it, I'm out. Peace to you.
Congrats! The most idiotic post of the day! Do you read what you posted??? WOW!
I think news is coming soon, unfortunately, I do not know when.
Call the TA and find number of outstanding shares. I think this will go up a lot soon.
The current bid at 350,000,000 is one-half the float!
....but woe to those who are short, they must also come up with dividend shares.
If the company choose to do a reverse split in the next few months, do these preferred shares split?
It's odd that this press release is Just a few days after the failed Phase 3 clinical trial.
Could they be setting up to seize an opportunity?
Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis
Eleven Biotherapeutics, Inc. (EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced top-line results from the Phase 3 clinical trial of its lead drug candidate, isunakinra (EBI-005), for the treatment of severe allergic conjunctivitis. In this trial, there were no statistically significant differences between the isunakinra treated group and the vehicle control group on the primary endpoint of ocular itching or on any secondary endpoints. Isunakinra was generally well tolerated, with 94% of the patients completing the trial and there were no serious adverse events reported.
The Albumedix deal is no small accomplishment. Novozymes is based in Denmark and they recently spun off Albumedix. I think they will buy out EBIO as a way to get a fast track Nasdaq listing in the states.
Novozymes separates its biopharma activities to form independent company
The new stand-alone company Albumedix will continue to develop albumin-based products and technologies for the pharmaceutical industry.
19. January 2016
CORPORATE NEWS
Today, Novozymes announced it has separated its biopharma activities into an independent company called Albumedix. The new company will be fully owned by Novozymes.
“Over the past nine years, our work in albumin has resulted in a series of new discoveries and technologies, which have led to agreements with major pharmaceutical and biotech companies,” says Thomas Videbæk, Executive Vice President for Business Development at Novozymes. “The business is in good shape with great prospects to make a real difference for patients all over the world. We believe it is now ready to be developed further outside Novozymes, where it will have the best possible growth conditions.”
Albumedix to accelerate Veltis® for half-life extension
Albumedix will continue to develop its market leading position within recombinant albumin-based products and technologies. Albumin is a naturally occurring protein that can be found in human blood.
Named Recombumin®, Albumedix’s recombinant albumins are used in the pharmaceutical industry to stabilize drugs and vaccines. For example, since 2006, Merck has used Albumedix’s solutions to produce two vaccines used to treat millions of children worldwide against measles, mumps, rubella and chicken pox.
Albumin can also be used to extend the half-life of pharmaceuticals to prolong the drugs’ effect and Albumedix offers a first and second generation version of this drug delivery technology under the name Veltis. In 2014, Veltis got its commercial breakthrough when GlaxoSmithKline launched a diabetes drug that utilizes the technology, allowing patients to dose weekly instead of daily. Today, Albumedix has a growing pipeline of partner-driven drug candidates evaluating Veltis.
In addition to providing albumin-based solutions to the pharmaceutical industry, Albumedix will initiate the exploration of early stage clinical drug development based on its Veltis technology and relevant drug candidates.
Experienced management team and board
Albumedix will be led by CEO Peter Rosholm, who previously headed Novozymes’ Biopharma business. The leadership team will report to an independent board consisting of three directors from the pharmaceutical industry and two representatives from Novozymes.
The Chairman of the Board, Don deBethizy, brings more than 15 years of experience in managing and financing life science related technologies, and has played a key role in building and advising several life science companies.
“I see a promising future for Albumedix, and together with Don deBethizy and the rest of the team I look forward to expanding our role in the pharmaceutical industry. With our heritage, expertise in albumin, and skilled employees, we have a strong foundation for developing superior biotherapeutics for patients,” says Peter Rosholm.
Albumedix will be headquartered in Lyngby, Denmark, with R&D and production facilities in Nottingham, UK. The company will employ approximately 100 people.
Novozymes retains full ownership of Albumedix and the newly created company’s financial results will continue to be consolidated into Novozymes’ reporting. The formation of Albumedix is not expected to impact Novozymes’ financial results for 2016.
Eleven Biotherapeutics Incorporated (NASDAQ:EBIO) Sellers Covered 29.73% of Their Shorts
MARCH 19, 2016 BY STAFF WRITER IN STOCK NEWS · 0 COMMENT
The stock of Eleven Biotherapeutics Incorporated (NASDAQ:EBIO) registered a decrease of 29.73% in short interest. EBIO’s total short interest was 286,900 shares in March as published by FINRA. Its down 29.73% from 408,300 shares, reported previously. With 555,100 shares average volume, it will take short sellers 1 days to cover their EBIO’s short positions. The short interest to Eleven Biotherapeutics Incorporated’s float is 4.45%. The stock 0.03% or $0 on March 18, hitting $0.392. It is down 92.16% since August 13, 2015 and is downtrending. It has underperformed by 89.98% the S&P500.
Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $7.80 million. The Firm through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. It currently has negative earnings. The Firm designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
The institutional sentiment decreased to 0.64 in 2015 Q3. Its down 0.29, from 0.93 in 2015Q2. The ratio worsened, as 16 funds sold all Eleven Biotherapeutics Inc shares owned while 6 reduced positions. 6 funds bought stakes while 8 increased positions. They now own 18.60 million shares or 31.23% more from 14.17 million shares in 2015Q2.
Flagship Ventures 2007 General Partner Llc holds 2.89% of its portfolio in Eleven Biotherapeutics Inc for 1.91 million shares. Third Rock Ventures Llc owns 4.84 million shares or 1.09% of their US portfolio. Moreover, Rotella Capital Management Inc. has 0.15% invested in the company for 190,947 shares. The California-based Redmile Group Llc has invested 0.04% in the stock. Sabby Management Llc, a New Jersey-based fund reported 171,541 shares.
Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Eleven Biotherapeutics was the topic in 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc.
I am unsure, but I hope for acquisitions. I think the float of this was soaked up in early January. There were rumors of such and/or a share buyback, etc. Based on their earlier announcement last week, I suspect we will be hearing from them soon. Additionally, I think the chart looks amazing.
I added another 0.5M this morning. Slap
...and I almost bought this. Glad I didn't.
Felt the same way
20% per day - no complaints.
OT
This is exactly my point. I don't know of any.
Here we have a CEO who wants to bring out great information about her company and each time she had an opportunity to talk, it was followed by goofy responses.
IMO, serious investors would be put off - the interview was not professional. Furthermore, she could have grabbed a camera and did a much better interview by herself. Then, she could publish the video directly to the company website, YouTube, and/or use a medium such as iHub to relay information to the investment community.
I'm certain that iIHub has made a fortune with ads and marketing, but they are missing the boat. I think if iHub would offer a professional interview service, they could be making some serious bank. (I am unaware if iHub is already providing this service. If they are - insert foot in mouth.)
It would be advantageous to have CEO's use video to promote their company and tell the investment community directly where their company is headed. Press releases only provide the written word, however, a video of a CEO would also include body language. Personally, I think this venue would provide additional leverage to the investor and would make it easier to detect the BS stocks from those of a worthwhile investment.
This interview is pathetic. The CEO should have chosen a different medium to relay information. The two men are a complete waste of time.
IMO, maybe it's wishful thinking, but I'm seeing this to have the potential to pop up to a $0.015.
By chance, does anyone have a few recent historical charts that are similar to the DCAC trading environment? I want to look at results of other pincher plays and compare them to DCAC. Thank you!
Thank You. I appreciate all your efforts.
I've been watching DCAC for a month. This is the first OTC-BB stock I have ever bought. I jumped in today @12. Got any great pincher advice for a NewB to determine the new resistance levels?